FDA Approves Updated COVID-19 Vaccines for XFG Variant

FDA Approvals and Vaccine Formulations for 2026-27

According to statements released by the drugmakers, the FDA approvals target specific variants circulating globally. Pfizer and BioNTech announced that their mRNA-based Covid-19 vaccine targets the LP.8.1 strain, receiving authorization for adults 65 and older as well as individuals ages 5 through 64 with underlying health conditions. Moderna secured approval for two separate mRNA formulations: Spikevax, which targets the XFG subvariant for people ages 6 months through 64 with underlying conditions and those 65 and older, and mNexspike, approved for individuals ages 12 through 64 with underlying conditions alongside seniors. Meanwhile, Novavax received approval for its protein-based option, Nuvaxovid, targeting the JN.1 strain for everyone 65 and older and individuals ages 12 through 64 with high-risk conditions, per company disclosures.

Eligibility Shifts and Federal Recommendations in Limbo

Federal guidance regarding who should receive the shots has shifted significantly. According to the Centers for Disease Control and Prevention, the agency now recommends immunizations based on “individual-based decision making,” moving away from previous recommendations. Younger individuals with underlying conditions—such as asthma, heart, kidney, liver or lung disease, diabetes, obesity, and pregnancy—qualify based on manufacturer-specific age tiers. However, uncertainty surrounds whether the administration will issue updated formal recommendations for the 2026-27 season. A CDC advisory panel remains in limbo following a March ruling that blocked Health Secretary Robert F Kennedy Jr’s appointment of a new slate of vaccine advisors.

Insurance Coverage Questions and Current Virus Activity

The absence of a functioning CDC advisory panel creates potential hurdles for consumer access and reimbursement. Insurers are typically required to cover vaccines recommended by the panel, leaving industry stakeholders uncertain about coverage mandates for the updated shots in the absence of a formal endorsement. On the epidemiological front, CDC data shows that current Covid-19 activity levels remain low overall, though wastewater monitoring and testing metrics indicate rising trends in recent weeks. According to CDC test positivity data for the week ending August 15, positivity approached 5% for the first time since early February, with climbing numbers recorded across every state.

Frequently Asked Questions

Who is currently eligible to receive the updated Covid-19 vaccines?

The FDA approved the updated shots for individuals 65 and older, as well as younger people with underlying health conditions. Age approvals vary by manufacturer, with Moderna starting at six months, Pfizer at age five, and Novavax at age 12.

View this post on Instagram about updated covid vaccines variant, FDA Covid-19 vaccines

Which coronavirus strains do the new vaccines target?

According to manufacturer announcements, the approved vaccines target circulating strains including the XFG subvariant, the LP.8.1 strain, and the JN.1 coronavirus strain.

When will the updated vaccines be available at pharmacies?

According to health experts, manufacturers are shipping doses immediately, and the vaccines are expected to hit pharmacies and doctors’ offices starting in September.

Will health insurance cover the updated 2026-27 shots?

While insurance companies have indicated that they will continue to cover the shot, ongoing uncertainty surrounding the CDC advisory panel has left questions about coverage mandates open.